الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> p53>>MB710

MB710

رقم الكتالوجGC62629

MB710 ، مشتق أمينوبنزوثيازول ، هو عامل استقرار لطفرة p53 المسرطنة Y220Cترتبط MB710 بإحكام بجيب Y220C وتستقر في p53-Y220C ، مع Kd 4.1μMيُظهر MB710 نشاطًا مضادًا للسرطان في خطوط الخلايا p53-Y220C

Products are for research use only. Not for human use. We do not sell to patients.

MB710 التركيب الكيميائي

Cas No.: 2230044-57-0

الحجم السعر المخزون الكميّة
5 mg
540٫00
متوفر
10 mg
945٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1?μM. MB710 shows anticancer activity in p53-Y220C cell lines[1].

MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all cell lines tested at concentrations up to 60?μM, while showing initial selective viability reduction at higher concentrations[1].MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC50s of 90, 120, >120, >120 μM, respectively[1].MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C[1].

[1]. Baud MGJ, et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem. 2018;152:101-114.

مراجعات

Review for MB710

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MB710

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.